Shares of 23andMe are now worth pennies. The company’s valuation has plummeted 99% from its $6 billion peak shortly after the company went public in 2021. ... What is the company’s plan for all the data it has collected since it was founded in 2006? ... When signing up for the service, about 80% of 23andMe’s customers have opted in to having their genetic data analyzed for medical research. The company has an agreement with pharmaceutical giant GlaxoSmithKline, or GSK, that allows the drugmaker to tap the tech company’s customer data to develop new treatments for disease. ...HIPAA, does not...